Cross sectional study on proportion of sulfonylureas among various oral antidiabetic drugs using for Japanese patients with type 2 diabetes, analyzed from NSAID Study-2.
Body Mass Index (BMI)
General practitioners
Glimepiride
HbA1c
Nationwide survey
Oral antidiabetic therapy
Sulfonylurea
Type 2 diabetes mellitus
Journal
Diabetology international
ISSN: 2190-1678
Titre abrégé: Diabetol Int
Pays: Japan
ID NLM: 101553224
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
06
04
2021
accepted:
29
06
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
We aimed to investigate the certainty of using sulfonylureas in Japanese patients with type 2 diabetes mellitus (T2DM) by analyzing data from the 2018 Nationwide Survey on Actual Intervention for T2DM by Japanese Practitioners (NSAID Study). Of the 6525 and 1545 participants in the NSAID Study under the care of general practitioners (GP) and diabetes specialists (SP), respectively, we included 5423 (83.1%) and 1058 (68.5%) patients who were treated with only oral antidiabetic drugs (OADs) by GPs and SPs, respectively, in the analysis. Among the seven OAD classes in monotherapy, sulfonylureas were the third and fifth most prescribed OADs by GPs (7.1%) and SPs (6.4%), respectively. Sulfonylurea usage increased with combination therapy. Glimepiride was the most commonly prescribed sulfonylurea. Patients who used sulfonylureas had higher hemoglobin A1c (HbA1c) levels and lower body mass indices (BMIs) than patients who did not use sulfonylureas. The results of this study clearly demonstrated that, among the OADs, sulfonylureas were not frequently used in monotherapy, although the opportunity of using sulfonylurea increased with the number of OADs prescribed in combination therapies by both GPs and SPs in Japan. Moreover, low-dose glimepiride was the most-prescribed sulfonylurea for Japanese T2DM patients, especially for those who were lean and had higher HbA1c levels.
Identifiants
pubmed: 35059253
doi: 10.1007/s13340-021-00520-7
pii: 520
pmc: PMC8733091
doi:
Types de publication
Journal Article
Langues
eng
Pagination
169-176Informations de copyright
© The Japan Diabetes Society 2021.
Déclaration de conflit d'intérêts
Conflict of interestS.S. received speaker honoraria from Novo Nordisk and Sanofi-Aventis for lectuures and Y.M. received speaker honoraria from Takeda for lectures. There are no other potential conflicts of interest.
Références
J Natl Med Assoc. 2003 Sep;95(9):774, 779-89
pubmed: 14527045
Diabetol Int. 2020 Jul 24;11(3):165-223
pubmed: 32802702
J Diabetes Investig. 2014 Sep;5(5):581-7
pubmed: 25411627
J Diabetes Complications. 2004 Nov-Dec;18(6):367-76
pubmed: 15531188
J Diabetes Investig. 2012 Jun 6;3(3):271-5
pubmed: 24843576
PLoS One. 2014 Feb 12;9(2):e82880
pubmed: 24533045
BMJ. 2012 Mar 12;344:e1369
pubmed: 22411919
Diabetes Res Clin Pract. 1999 May;44(2):129-36
pubmed: 10414932
Medicine (Baltimore). 2017 Feb;96(7):e6122
pubmed: 28207538
Diabetes Care. 2020 Feb;43(2):487-493
pubmed: 31857443
Diabet Med. 1998 Jul;15(7):539-53
pubmed: 9686693
Biochem Pharmacol. 2002 Jun 1;63(11):1921-35
pubmed: 12093468
Ann Intern Med. 2016 Jun 7;164(11):740-51
pubmed: 27088241
Diabetes Res Clin Pract. 2004 Dec;66 Suppl 1:S37-43
pubmed: 15563978
BMJ. 2018 Jul 18;362:k2693
pubmed: 30021781
Diabetes Technol Ther. 2013 Apr;15(4):335-41
pubmed: 23480592
J Diabetes Complications. 1994 Oct-Dec;8(4):201-3
pubmed: 7833494
Diabetes Obes Metab. 2018 Dec;20(12):2830-2839
pubmed: 29974673
J Diabetes Investig. 2018 Mar 26;:
pubmed: 29582574
Diabetes Ther. 2020 Jul;11(7):1497-1511
pubmed: 32440836
J Diabetes Investig. 2016 May;7(3):386-95
pubmed: 27330726
Diabete Metab. 1993 Nov-Dec;19(6):547-59
pubmed: 8026606
Horm Metab Res. 1996 Sep;28(9):496-507
pubmed: 8911987
Ann Intern Med. 1993 Feb 1;118(3):169-72
pubmed: 8417634
Diabetes Technol Ther. 2014 Jul;16(7):442-6
pubmed: 24528246
Int Heart J. 2013;54(2):93-7
pubmed: 23676369
Endocr J. 2010;57(6):499-507
pubmed: 20208396